病理性近视黄斑脉络膜新生血管的治疗

Therapy of Choroidal Neovascularization Secondary to Pathological Myopia

病理性近视(PM)黄斑脉络膜新生血管(CNV)成为世界上近视患者视力丧失的主要原因之一,尤其是亚洲年轻患者(年龄<50岁)。CNV的早期发现和及时治疗,可以大大降低PM的致盲率,改善患者的视觉质量。临床上尝试了不同的治疗方法,如光动力学疗法、抗血管内皮生长因子药物治疗及联合治疗等,治疗后视功能有所提高。然而,长期安全性及有效性仍未认可。

Choroidal neovascularization（ CNV ）secondary to pathological myopia（PM） is one of the leading causes of irreversible visual impairment worldwide, especially for patients younger than 50 years old in Asian countries. Early diagnosis and timely therapeutic strategy for CNV may greatly decline the risks of visual loss and improve visual quality to some extent. Different treatment modalities for pathological myopic CNV have been attempted in clinical such as photodyuamic therapy, inhibitors of vascular endothelial growth factor and combined therapies. Visual outcome of these therapies has been reported to be better. However, the long-term safety and efficacy still needs recognition.